BACKGROUND
Pembrolizumab plus chemotherapy with a platinum-based agent and pemetrexed is a widely used standard first-line treatment option for patients with programmed death ligand 1 (PD-L1)-negative advanced nonsquamous non-small-cell lung cancer (NSCLC) without targetable genomic alterations, but outcomes remain sub...
Fei Zhou, Xiang-Jiao Meng, Qing-Qing Ding et al.· New England Journal of Medic...· 0 citations
PURPOSE
We report the results of a Phase 1 study of TAVO412, an anti-EGFR, cMET, and VEGF-A multi-specific antibody.
PATIENTS AND METHODS
Patients of age ≥18 years with advanced solid tumors refractory to standard therapies were enrolled (TAVO412-CN001, NCT06761651). The study used a standard 3 + 3 design for dose-es...
Chao Han, Hong Xie, Yan Yu et al.· The Oncologist· 0 citations
PURPOSE
MET amplification accounts for up to 30% of acquired resistance to EGFR-TKI, especially following third-generation EGFR-TKI treatment, yet precision-targeted therapeutic options remain limited. Early-phase studies demonstrated promising antitumor activity with the MET-TKI dalmelitinib combined with the third-ge...
Zi-Ming Li, Xiao-Rong Dong, Yan Yu et al.· Journal of Clinical Oncology· 0 citations
BACKGROUND
Ruzaltatug rezetecan is a novel HER3-directed antibody-drug conjugate that has shown promising antitumour activity and manageable safety in pretreated EGFR-.mutated non-small-cell lung cancer (NSCLC) in a phase 1 trial. We aimed to compare the efficacy and safety of ruzaltatug rezetecan with chemotherapy in...
Chong-Rui Xu, Yan Zhang, G. Lin et al.· The Lancet· 1 citation
Findings support sutetinib as a potential treatment option for this molecularly heterogeneous population of adults with locally advanced or metastatic NSCLC harboring uncommon EGFR mutations and demonstrate clinically meaningful antitumor activity with a manageable safety profile.
Feng-Ying Wu, Wei Zhang, Yan-Qiu Zhao et al.· Journal of Thoracic Oncology· 0 citations
Lung cancer brain metastasis (LCBM) is a major cause of cancer-related mortality, driven by the restrictive blood–brain barrier (BBB), an immunosuppressive microenvironment, and dynamic metabolic reprogramming. Increasing evidence suggests that LCBM is governed by coordinated interactions among neural, immune, and vasc...
Jiaojiao Li, Mingjun Xu, Lei Wang et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.